A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations.

10243AAML1831-NCT04293562OpenA Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations.AAML1831NCT04293562NationalChildrenTreatmentIIILymphoid Leukemia; Non-Hodgkin LymphomaPudela, CaileighGeorgetown University Medical Center; Lombardi Comprehensive Cancer CenterPediatricsOncology GroupLombardi Comprehensive Cancer Center (LCCC)2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>